Tools
Enterohemorrhagic Escherichia coli
Introduction
Escherichia coli is a gram-negative, rod-shaped bacteria belonging to the genus Escherichia that commonly resides in the human colon. Shigatoxigenic along with verotoxigenic E. coli (STEC), (VTEC) are strains of E. coli that are known to produce Shiga toxin and Shiga-like toxin (verotoxin) respectively. The strains that cause ailments in humans are commonly known as enterohemorrhagic E. coli (EHEC). The terms mentioned above are often used interchangeably. EHEC serotype O157:H7 is a human pathogen found to be responsible for bloody diarrhea outbreaks and hemolytic uremic syndrome (HUS) worldwide. [1]
Etiology
Register For Free And Read The Full Article
Search engine and full access to all medical articles- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Etiology
The infections caused by E. coli O157:H7 range from asymptomatic to severe. Few individuals can develop potentially fatal complications like hemolytic uremic syndrome (HUS). Chronic renal pathology may persist at times among those that survive. Humans are known to acquire E. coli O157:H7 in multiple ways, for example, contaminated food and water and direct contact with infected animals and humans. Consumption of contaminated food like ground beef, dairy products, and fresh produce is responsible for the majority of the outbreaks. [2]
Cattle are considered as the principal reservoirs for E.coli O157:H7; contamination takes place through their use as food, their manure used as a fertilizer, and through water supplies contaminated by runoff from cattle farms. Although variation has been reported in fecal shedding of E. coli O157:H7 has been ranging from 0 to 80% among the cattle population, a seasonal pattern has also been shown, with prevalence increasing during summer months. Elevated temperature in summers might be responsible for favoring bacterial proliferation and survival.
Epidemiology
The Centers for Disease Control and Prevention (CDC) estimated that foodborne E. coli O157:H7 is responsible for over 63,000 illnesses per year that leads to more than 2100 hospitalizations and deaths in the United States. The economic burden of illness due to this bacteria resulting from medical expenses and death and loss of productivity is estimated to be $405 million per year. [3][4]
According to the 10 US sites of the Foodborne Diseases Active Surveillance Network (FoodNet) preliminary report of 2017, STEC was listed as one of the 9 pathogens commonly transmitted by food. As compared to the incidence 2014 through 2016 the incidence in 2017 was 28% higher. Fifty-seven cases of HUS were identified in 2016; the incidence was not significantly different from 2013 through 2015.
In Norway, HUS was labeled as the second most common cause of acute kidney infection (AKI) in children with an estimated average annual incidence of 0.5 cases per 100,000 children.
Pathophysiology
On entry, EHEC strains produce Shiga-like toxins (Stx) which mediate the dysregulation of membrane ion channels in the epithelial membrane of the intestine that leads to loss of ions and a massive amount of water. This toxin also acts as a cell transduction and immune modulator leading to pro-inflammatory and pro-apoptotic sequela. Endothelial lesions in the microvasculature of the kidney and less frequently of other organs are found to be responsible for sequela of the hemolytic uremic syndrome. The kidney and gastrointestinal (GI) tract are the most commonly affected organs in HUS, but evidence of central nervous system (CNS), pancreatic, skeletal, and myocardial involvement has also been shown in the studies conducted. The mechanism of this microvascular injury is unknown, but evidence shows that verocytotoxin plays a role in mediating cell injury with a resultant change in the normal anti-coagulant profile of the endothelial cell to a procoagulant state. [5]
After E. coli infection, several factors determine the progression of the disease to HUS like:
- Bacterial strain: Serotype O157:H7 is most often found to be responsible
- Age: The rate of progression to HUS is higher in young children. A study showed it to be 12.9% in children younger than 5 years of age, 6.8% in children between 5 to 10 years, 8% in children older than 10 years of age.
- Antibiotic: Treatment with antibiotic therapy for E. coli O157:H7 has shown to increase the risk of HUS
- Environmental and genetic factors
Histopathology
In the acute phase of HUS, specimens of the kidney show microvascular injury characterized by deposition of microthrombi along with detached and swollen glomerular endothelial cells associated with infiltration of inflammatory cells. Similar changes have been described in other organs. This shows that HUS is a multisystem disease characterized by endothelial cell injury. [6]
Toxicokinetics
Enterohemorrhagic E. coli is not invasive, making bacteremia rare. It adheres to mammalian cells, secreting bacterial proteins into host cells through a type III secretion system. Ribosome-inactivating Shiga-like toxins (Stx1 and Stx2) are secreted which are responsible for organ damage. Stx 2 has been found to be more often associated with severe disease. Shiga toxin consists of 2 subunits: A and B. Proteolysis further degrades subunit A into A1 and A2. In target organs, for example, the kidney, brain, and gut, subunit B attaches to glycolipid receptors on the cell surface. In humans, these receptors have been identified as Gb3 which are mainly expressed in kidney tubular cells, brain, and gut epithelium. The cytotoxicity is further amplified in the kidney due to the interplay of tumor necrosis factor-alpha. After it binds to the cell surface, Shiga toxin is endocytosed and transported to the Golgi apparatus and endoplasmic reticulum in a retrograde direction from there it is then translocated to the cytosol where it inactivates ribosomes and causes cell death. [5][7]
History and Physical
EHEC clinically manifests as bloody diarrhea (visibly bloody stool specimen) without fever and usually a white blood cell count above 10,000/microL at times associated with abdominal pain. The incubation period between exposure to EHEC and onset of symptoms is typically 3 to 4 days. [8][3][7]
HUS is a major complication of EHEC infection. It is a clinical triad of anemia secondary to hemolysis, impaired renal function, and thrombocytopenia mainly affecting young children. HUS following bloody diarrhea secondary to EHEC is called D+ HUS or typical HUS; whereas, HUS caused by other causes is referred to as D- HUS or atypical HUS.
Evaluation
Patients suspected of infection from EHEC are tested for Shiga toxin or EHEC by doing stool culture. Blood tests and urine tests are also conducted in patients presenting with HUS which can show low red blood cell and platelet count and assess renal functions respectively. [9]
Treatment / Management
Supportive treatment is provided to those having EHEC diarrhea.[5]
Electrolytes and water deficiency should be replaced, especially in patients with D+ HUS. The current advancements in dialysis and intensive care have reduced mortality, mainly in young children. The best option for children is peritoneal dialysis. Bilateral nephrectomy is life-saving and can control the spread of microvascular lesions when the kidneys are the main site of the disease involvement especially in cases of therapy-resistant malignant hypertension.[5] Because the prognosis is often severe, immediate supportive treatment may improve the outcome. Other supportive treatments available for patients with HUS are mainly dependent on their symptoms and mainly include:
- Red blood cell transfusions
- Platelet transfusions
- Plasma exchange
In general, the prevention of foodborne diseases must be based on good hygienic practices and control of the contamination of foods by biological and chemical hazards. This can be achieved most effectively through the application of food safety assurance programs. Vaccines for EHEC are under study but have not been approved by FDA yet.
Differential Diagnosis
In all patients with HUS symptoms, Shiga toxin/STEC should be tested along with ADAMTS13 activity as clinical presentation, and the organ involvement in hemolytic uremic syndrome and thrombotic thrombocytopenic purpura can overlap. In patients of unusual age or in whom diarrhea is absent anomalous or atypical E. coli, HUS is a possible diagnosis. [5]
Prognosis
Diagnosing EHEC infection early and starting prompt fluid replacement has shown to improve long-term outcomes by reducing damage to the kidney. Advancement in dialysis therapy and improved care of critically ill children have resulted in a significant reduction in acute mortality of HUS to such an extent that chronic complications in long-term survivors are becoming more apparent. [10]
Complications
Often, EHEC associated with bloody diarrhea can resolve without any long-term consequences. The prognosis is severe mainly in patients developing HUS. After being treated for HUS, some children can never recover renal functions and thus require long-term replacement therapies for renal functions whereas those who recover renal functions are at risk of late development of renal disease. Some children may have residual extrarenal problems including neurological defects, insulin-dependent diabetes mellitus, pancreatic insufficiency, or gastrointestinal complications. HUS is thus a disease with substantial mortality and multisystem morbidity. This shows that importance should be given to extra-renal manifestations in the acute phase and renal functions should be monitored in long-term follow-up of HUS patients. [11]
Deterrence and Patient Education
Taking measures like usage of drinkable water for food preparation, observing improved hygienic conditions during the slaughter of animals, use of appropriate measures of food processing, cooking food properly, educating/teaching food handlers and farm workers about the principles of food hygiene, and its application can significantly reduce the incidence of EHEC infections.
Pearls and Other Issues
EHEC is a foodborne disease that can be reduced by practicing good hygiene and controlling the contamination of food. It is a human pathogen found to be responsible for bloody diarrhea outbreaks and hemolytic uremic syndrome (HUS) worldwide. There is no specific treatment, but studies are being conducted. Supportive measurements are the mainstay of treatment.
Enhancing Healthcare Team Outcomes
The management of EHEC is interprofessional. For most patients, supportive treatment will suffice. Electrolytes and water deficiency should be replaced, especially in patients with D+ HUS. The current advancements in dialysis and intensive care have reduced mortality, mainly in young children. The best option for children is peritoneal dialysis. Bilateral nephrectomy is life-saving and can control the spread of microvascular lesions when the kidneys are the main site of the disease involvement especially in cases of therapy-resistant malignant hypertension. Because the prognosis is often severe, immediate supportive treatment may improve the outcome. Other supportive treatments available for patients with HUS are mainly dependent on their symptoms and may include plasma exchange and blood transfusions.
In general, the primary care provider and nurse practitioner should educate the patient on the prevention of foodborne diseases. This can be achieved most effectively through the application of food safety assurance programs. Vaccines for EHEC are under study but have not been approved by FDA yet.[12]
References
Ameer MA, Wasey A, Salen P. Escherichia coli (e Coli 0157 H7). StatPearls. 2024 Jan:(): [PubMed PMID: 29939622]
Beauvais W, Gart EV, Bean M, Blanco A, Wilsey J, McWhinney K, Bryan L, Krath M, Yang CY, Manriquez Alvarez D, Paudyal S, Bryan K, Stewart S, Cook PW, Lahodny G Jr, Baumgarten K, Gautam R, Nightingale K, Lawhon SD, Pinedo P, Ivanek R. The prevalence of Escherichia coli O157:H7 fecal shedding in feedlot pens is affected by the water-to-cattle ratio: A randomized controlled trial. PloS one. 2018:13(2):e0192149. doi: 10.1371/journal.pone.0192149. Epub 2018 Feb 7 [PubMed PMID: 29414986]
Level 1 (high-level) evidenceMarder Mph EP, Griffin PM, Cieslak PR, Dunn J, Hurd S, Jervis R, Lathrop S, Muse A, Ryan P, Smith K, Tobin-D'Angelo M, Vugia DJ, Holt KG, Wolpert BJ, Tauxe R, Geissler AL. Preliminary Incidence and Trends of Infections with Pathogens Transmitted Commonly Through Food - Foodborne Diseases Active Surveillance Network, 10 U.S. Sites, 2006-2017. MMWR. Morbidity and mortality weekly report. 2018 Mar 23:67(11):324-328. doi: 10.15585/mmwr.mm6711a3. Epub 2018 Mar 23 [PubMed PMID: 29565841]
Jenssen GR, Vold L, Hovland E, Bangstad HJ, Nygård K, Bjerre A. Clinical features, therapeutic interventions and long-term aspects of hemolytic-uremic syndrome in Norwegian children: a nationwide retrospective study from 1999-2008. BMC infectious diseases. 2016 Jun 13:16():285. doi: 10.1186/s12879-016-1627-7. Epub 2016 Jun 13 [PubMed PMID: 27297224]
Level 2 (mid-level) evidenceSalvadori M, Bertoni E. Update on hemolytic uremic syndrome: Diagnostic and therapeutic recommendations. World journal of nephrology. 2013 Aug 6:2(3):56-76. doi: 10.5527/wjn.v2.i3.56. Epub [PubMed PMID: 24255888]
Bystrom PV, Beck RJ, Prahlow JA. Hemolytic uremic syndrome caused by E. coli O157 infection. Forensic science, medicine, and pathology. 2017 Jun:13(2):240-244. doi: 10.1007/s12024-017-9852-y. Epub 2017 Mar 28 [PubMed PMID: 28352987]
Mayer CL, Leibowitz CS, Kurosawa S, Stearns-Kurosawa DJ. Shiga toxins and the pathophysiology of hemolytic uremic syndrome in humans and animals. Toxins. 2012 Nov 8:4(11):1261-87. doi: 10.3390/toxins4111261. Epub 2012 Nov 8 [PubMed PMID: 23202315]
Level 3 (low-level) evidenceGomes TA, Elias WP, Scaletsky IC, Guth BE, Rodrigues JF, Piazza RM, Ferreira LC, Martinez MB. Diarrheagenic Escherichia coli. Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]. 2016 Dec:47 Suppl 1(Suppl 1):3-30. doi: 10.1016/j.bjm.2016.10.015. Epub 2016 Nov 5 [PubMed PMID: 27866935]
Cheong HI, Jo SK, Yoon SS, Cho H, Kim JS, Kim YO, Koo JR, Park Y, Park YS, Shin JI, Yoo KH, Oh D. Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in Korea. Journal of Korean medical science. 2016 Oct:31(10):1516-28. doi: 10.3346/jkms.2016.31.10.1516. Epub [PubMed PMID: 27550478]
Level 1 (high-level) evidenceGrisaru S. Management of hemolytic-uremic syndrome in children. International journal of nephrology and renovascular disease. 2014:7():231-9. doi: 10.2147/IJNRD.S41837. Epub 2014 Jun 12 [PubMed PMID: 24966691]
Rahal EA, Kazzi N, Nassar FJ, Matar GM. Escherichia coli O157:H7-Clinical aspects and novel treatment approaches. Frontiers in cellular and infection microbiology. 2012:2():138. doi: 10.3389/fcimb.2012.00138. Epub 2012 Nov 15 [PubMed PMID: 23162800]
Saeedi P, Yazdanparast M, Behzadi E, Salmanian AH, Mousavi SL, Nazarian S, Amani J. A review on strategies for decreasing E. coli O157:H7 risk in animals. Microbial pathogenesis. 2017 Feb:103():186-195. doi: 10.1016/j.micpath.2017.01.001. Epub 2017 Jan 3 [PubMed PMID: 28062285]
Level 3 (low-level) evidenceRangel JM,Sparling PH,Crowe C,Griffin PM,Swerdlow DL, Epidemiology of Escherichia coli O157:H7 outbreaks, United States, 1982-2002. Emerging infectious diseases. 2005 Apr; [PubMed PMID: 15829201]
Phillips AD, Navabpour S, Hicks S, Dougan G, Wallis T, Frankel G. Enterohaemorrhagic Escherichia coli O157:H7 target Peyer's patches in humans and cause attaching/effacing lesions in both human and bovine intestine. Gut. 2000 Sep:47(3):377-81 [PubMed PMID: 10940275]
Foster JW, Escherichia coli acid resistance: tales of an amateur acidophile. Nature reviews. Microbiology. 2004 Nov; [PubMed PMID: 15494746]
Nakanishi N, Tashiro K, Kuhara S, Hayashi T, Sugimoto N, Tobe T. Regulation of virulence by butyrate sensing in enterohaemorrhagic Escherichia coli. Microbiology (Reading, England). 2009 Feb:155(Pt 2):521-530. doi: 10.1099/mic.0.023499-0. Epub [PubMed PMID: 19202100]
Jacewicz MS, Acheson DW, Mobassaleh M, Donohue-Rolfe A, Balasubramanian KA, Keusch GT. Maturational regulation of globotriaosylceramide, the Shiga-like toxin 1 receptor, in cultured human gut epithelial cells. The Journal of clinical investigation. 1995 Sep:96(3):1328-35 [PubMed PMID: 7657808]
Schüller S, Heuschkel R, Torrente F, Kaper JB, Phillips AD. Shiga toxin binding in normal and inflamed human intestinal mucosa. Microbes and infection. 2007 Jan:9(1):35-9 [PubMed PMID: 17208032]
Robson WL, Fick GH, Wilson PC. Prognostic factors in typical postdiarrhea hemolytic-uremic syndrome. Child nephrology and urology. 1988-1989:9(4):203-7 [PubMed PMID: 3255484]
Geelen JM, van der Velden TJ, van den Heuvel LP, Monnens LA. Interactions of Shiga-like toxin with human peripheral blood monocytes. Pediatric nephrology (Berlin, Germany). 2007 Aug:22(8):1181-7 [PubMed PMID: 17574480]
Ståhl AL, Sartz L, Nelsson A, Békássy ZD, Karpman D. Shiga toxin and lipopolysaccharide induce platelet-leukocyte aggregates and tissue factor release, a thrombotic mechanism in hemolytic uremic syndrome. PloS one. 2009 Sep 11:4(9):e6990. doi: 10.1371/journal.pone.0006990. Epub 2009 Sep 11 [PubMed PMID: 19750223]
Mele C, Remuzzi G, Noris M. Hemolytic uremic syndrome. Seminars in immunopathology. 2014 Jul:36(4):399-420. doi: 10.1007/s00281-014-0416-x. Epub 2014 Feb 14 [PubMed PMID: 24526222]
Scheiring J, Andreoli SP, Zimmerhackl LB. Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS). Pediatric nephrology (Berlin, Germany). 2008 Oct:23(10):1749-60. doi: 10.1007/s00467-008-0935-6. Epub 2008 Aug 13 [PubMed PMID: 18704506]
Smith KE, Wilker PR, Reiter PL, Hedican EB, Bender JB, Hedberg CW. Antibiotic treatment of Escherichia coli O157 infection and the risk of hemolytic uremic syndrome, Minnesota. The Pediatric infectious disease journal. 2012 Jan:31(1):37-41. doi: 10.1097/INF.0b013e31823096a8. Epub [PubMed PMID: 21892124]
Wong CS, Mooney JC, Brandt JR, Staples AO, Jelacic S, Boster DR, Watkins SL, Tarr PI. Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2012 Jul:55(1):33-41. doi: 10.1093/cid/cis299. Epub 2012 Mar 19 [PubMed PMID: 22431799]
Hosler GA, Cusumano AM, Hutchins GM. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases. Archives of pathology & laboratory medicine. 2003 Jul:127(7):834-9 [PubMed PMID: 12823037]
Level 3 (low-level) evidenceButt S, Jenkins C, Godbole G, Byrne L. The epidemiology of Shiga toxin-producing Escherichia coli serogroup O157 in England, 2009-2019. Epidemiology and infection. 2022 Feb 11:150():e52. doi: 10.1017/S0950268822000206. Epub 2022 Feb 11 [PubMed PMID: 35241189]
Kaper JB, Nataro JP, Mobley HL. Pathogenic Escherichia coli. Nature reviews. Microbiology. 2004 Feb:2(2):123-40 [PubMed PMID: 15040260]
Conway T, Cohen PS. Commensal and Pathogenic Escherichia coli Metabolism in the Gut. Microbiology spectrum. 2015 Jun:3(3):. doi: 10.1128/microbiolspec.MBP-0006-2014. Epub [PubMed PMID: 26185077]
Mittal N,Budrene EO,Brenner MP,Van Oudenaarden A, Motility of Escherichia coli cells in clusters formed by chemotactic aggregation. Proceedings of the National Academy of Sciences of the United States of America. 2003 Nov 11; [PubMed PMID: 14597724]
Shiomi D,Mori H,Niki H, Genetic mechanism regulating bacterial cell shape and metabolism. Communicative [PubMed PMID: 19641734]
Palmer C, Bik EM, DiGiulio DB, Relman DA, Brown PO. Development of the human infant intestinal microbiota. PLoS biology. 2007 Jul:5(7):e177 [PubMed PMID: 17594176]
Kintz E, Brainard J, Hooper L, Hunter P. Transmission pathways for sporadic Shiga-toxin producing E. coli infections: A systematic review and meta-analysis. International journal of hygiene and environmental health. 2017 Jan:220(1):57-67. doi: 10.1016/j.ijheh.2016.10.011. Epub 2016 Nov 6 [PubMed PMID: 27842895]
Level 1 (high-level) evidenceBlanco JE, Blanco M, Blanco J. [Enterotoxigenic, verotoxigenic, and necrotoxigenic Escherichia coli in food and clinical samples. Role of animals as reservoirs of strains pathogenic for humans]. Microbiologia (Madrid, Spain). 1995 Mar:11(1):97-110 [PubMed PMID: 7546450]
Level 3 (low-level) evidence